XENE (Xenon Pharmaceuticals) Investments And Advances : $141.50 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Investments And Advances?

Xenon Pharmaceuticals's Investments And Advances for the quarter that ended in Mar. 2025 was $141.50 Mil.

Xenon Pharmaceuticals's quarterly Investments And Advances declined from Sep. 2024 ($149.32 Mil) to Dec. 2024 ($127.50 Mil) but then increased from Dec. 2024 ($127.50 Mil) to Mar. 2025 ($141.50 Mil).

Xenon Pharmaceuticals's annual Investments And Advances increased from Dec. 2022 ($128.68 Mil) to Dec. 2023 ($292.79 Mil) but then declined from Dec. 2023 ($292.79 Mil) to Dec. 2024 ($127.50 Mil).

Xenon Pharmaceuticals Investments And Advances Historical Data

The historical data trend for Xenon Pharmaceuticals's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Investments And Advances Chart

Xenon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Investments And Advances

Get a 7-Day Free Trial

128.68

292.79

127.50

Xenon Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Investments And Advances	Get a 7-Day Free Trial															185.84	129.06	149.32	127.50	141.50

Xenon Pharmaceuticals Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Xenon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

XP0:Germany

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Executives

Ian Mortimer	director, officer: PRESIDENT & CEO	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Sherry Aulin	officer: Chief Financial Officer	200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Gary Patou	director
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Sherrington Robin	officer: SVP Bus. & Corp. Development	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover	director	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Simon N. Pimstone	director	200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney	officer: Chief Medical Officer	200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio	officer: Chief Legal Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
James R. Empfield	officer: SVP, Drug Discovery	200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von	officer: Chief Commercial Officer	200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W